Clinical Report: Practice Management for Photobiomodulation of the Retina

Overview

Photobiomodulation (PBM) has emerged as a novel treatment for intermediate dry age-related macular degeneration (AMD), showing potential to improve visual function. The Valeda Light Delivery System received FDA authorization in November 2024, marking a significant advancement in treatment options beyond traditional methods.

Background

The management of dry AMD is critical as it can lead to significant visual impairment. Traditional treatments have been limited to vitamins and lifestyle changes, making the introduction of PBM a noteworthy development. This therapy offers a non-invasive alternative that does not require anesthesia, which is particularly advantageous in clinical settings.

Data Highlights

No numerical data available in the source material.

Key Findings

• The Valeda Light Delivery System received FDA authorization in November 2024.
• PBM has shown potential to improve visual function in patients with intermediate dry AMD.
• Medicare does not cover claims for reimbursement of a hospital facility fee for PBM.
• State laws define the roles of healthcare workers in administering PBM, with significant variations across states.
• Category III CPT code 0936T was introduced for billing PBM procedures.

Clinical Implications

Healthcare providers should be aware of the specific state regulations governing the administration of PBM. Additionally, understanding the reimbursement landscape is crucial for integrating PBM into practice effectively.

Conclusion

PBM represents a promising advancement in the treatment of dry AMD, but its implementation requires careful consideration of regulatory and reimbursement factors.

References

1. Retinal Physician, 2025 -- Practice Management for Photobiomodulation of the Retina
2. Retinal Physician, 2026 -- Can Photobiomodulation Regulate Dry AMD?
3. JAMA Ophthalmology, 2024 -- Photobiomodulation for Age-Related Macular Degeneration
4. Retinal Physician — Can Photobiomodulation Regulate Dry AMD?
5. Retinal Physician — Photobiomodulation as an Innovative and Promising Treatment for Retinal Disease
6. Retinal Physician — Photobiomodulation as an Innovative and Promising Treatment for Retinal Disease
7. Photobiomodulation for Age-Related Macular Degeneration | Ophthalmology | JAMA Ophthalmology | JAMA Network
8. Long-term Efficacy and Safety of Photobiomodulation in Dry Age-Related Macular Degeneration (LIGHTSITE III: 24-Month Analysis) - PubMed
9. Practice Management for Photobiomodulation of the Retina | Retinal Physician